NVP-CGM097-sulfate-CGM097-sulfate-DataSheet-生命科学试剂-MedChemExpress_第1页
NVP-CGM097-sulfate-CGM097-sulfate-DataSheet-生命科学试剂-MedChemExpress_第2页
NVP-CGM097-sulfate-CGM097-sulfate-DataSheet-生命科学试剂-MedChemExpress_第3页
NVP-CGM097-sulfate-CGM097-sulfate-DataSheet-生命科学试剂-MedChemExpress_第4页
全文预览已结束

下载本文档

版权说明:本文档由用户提供并上传,收益归属内容提供方,若内容存在侵权,请进行举报或认领

文档简介

1、Hotline: 400-820-3792Inhibitors Agonists Screening Librarieswww.MedChemENVP-CGM097 sulfateCat. No.: HY-15954BCAS No.: 1313367-56-4Synonyms: CGM097 sulfate分式: CHClNOS分量: 757.34作靶点: MDM-2/p53作通路: Apoptosis储存式: Powder -20C 3 years4C 2 yearsIn solvent -80C 6 months-20C 1 month溶解性数据体外实验 H2O : 140 mg/mL (

2、184.86 mM)* means soluble, but saturation unknown.Mass Solvent1 mg 5 mg 10 mg Concentration制备储备液1 mM 1.3204 mL 6.6021 mL 13.2041 mL5 mM 0.2641 mL 1.3204 mL 2.6408 mL10 mM 0.1320 mL 0.6602 mL 1.3204 mL请根据产品在不同溶剂中的溶解度,选择合适的溶剂配制储备液,并请注意储备液的保存式和期限。BIOLOGICAL ACTIVITY物活性 NVP-CGM097是有效,选择性的MDM2抑制剂;IC50值为1

3、.7 nM。IC50 & Target IC50 & Target: IC50: 1.70.1 nM (hMDM2) 1体外研究NVP-CGM097 binds to human MDM2 with an IC50 of 1.7 nM and shows high selectivity over MDM41/2 Master of Small Molecules 您边的抑制剂师www.MedChemE(IC50=2000 nM). NVP-CGM097 is about four times more potent than Nutlin-3a (IC50=8 nM). In additio

4、n,NVP-CGM097 shows no significant activity against Bcl-2:Bak, Bcl-2:Bad, Mcl-1:Bak, Mcl-1:NOXA,XIAP:BIR3, and c-IAP:BIR3 protein-protein interactions. NVP-CGM097 significantly inhibits the proliferationof cells expressing wild-type p53, while sparing the p53 null cells with a 35-58-fold difference.

5、NVP-CGM097is able to significantly redistribute wild-type p53 into the cell nucleus with an IC50 of 0.224 M, demonstratingits ability to inhibit the p53:MDM2 interaction in living cells. NVP-CGM097 significantly inhibits theproliferation of cells expressing wild-type p53, while sparing the p53 null

6、cells with a 35-58-fold difference.NVP-CGM097 inhibtis HCT116 (p53WT/WT) with IC50 of 454136 nM 1.体内研究 NVP-CGM097 is able to inhibit the interaction between p53 and MDM2 and reactivate the p53 pathway in aMDM2-amplified SJSA-1 human tumor model, as judged by elevation of p21 mRNA levels, apharmacody

7、namic (PD) indicator for p53 activity. p21 mRNA levels are found to increase concomitantly withlevels of NVP-CGM097 in tumor-bearing rats dosed at 30 mg/kg. The PD response is biphasic and prolongedup to 24 h. Additional p53 target genes such as MDM2 and PUMA mRNA levels are assessed in the tumorsam

8、ples as well and showed a similar behavior. Daily treatment with NVP-CGM097 dose dependently andsignificantly inhibits SJSA-1 tumor growth in rats. It promotes stable disease at 20 mg/kg, which is associatedwith a plasma AUC0-24 of 163 Mh. After iv administration, the total blood clearance (CL) of N

9、VP-CGM097is 5 mL/min per kg for mouse, 7 mL/min per kg for rat, 3 mL/min per kg for dog, and 4 mL/min per kg formonkey. The apparent terminal half-life (t1/2) is long in rodents and monkey (6-12 h) but is comparativelylonger in dogs (20 h). After oral dosing, NVP-CGM097 is well absorbed with Tmax oc

10、curring between 1 and4.5 h in all species tested 1.PROTOCOLCell Assay 1 Two pairs of cell lines are used to assess NVP-CGM097 p53-dependent antiproliferative effects: (1) anisogenic pair of HCT116 cell lines either expressing wild-type p53 or knocked-out for the p53 gene and (2) anonisogenic pair of

11、 osteosarcoma cell lines either endogenously expressing wild-type p53 and amplified forMDM2 (SJSA-1 cells) or null for p53 (SAOS-2 cells) 1.MCE has not independently confirmed the accuracy of these methods. They are for reference only.Animal Female athymic rats bearing subcutaneous xenotransplants o

12、f SJSA-1 tumors (n=5-12) are treated at 5, 10,Administration 1 20, or 30 mg/kg or three times a week on Monday, Wednesday, and Friday (3qw M, W, F) at 30 or 70 mg/kgpo for 14 days. Plasma AUCs are determined at the end of the study. Positive numbers indicate thepercentage of tumor growth inhibition

13、(T/C); negative numbers indicate the percentage of tumor regression1.MCE has not independently confirmed the accuracy of these methods. They are for reference only.REFERENCES1. Holzer P, et al. Discovery of a Dihydroisoquinolinone Derivative (NVP-CGM097): A Highly Potent and Selective MDM2 InhibitorUndergoing Phase 1 Clinical Trials in p53wt Tumors. J Med Chem. 2015 Aug 27;58(16):6348-58.McePdfHeight2/2 Master of Small Molecules 您边的抑制剂师

温馨提示

  • 1. 本站所有资源如无特殊说明,都需要本地电脑安装OFFICE2007和PDF阅读器。图纸软件为CAD,CAXA,PROE,UG,SolidWorks等.压缩文件请下载最新的WinRAR软件解压。
  • 2. 本站的文档不包含任何第三方提供的附件图纸等,如果需要附件,请联系上传者。文件的所有权益归上传用户所有。
  • 3. 本站RAR压缩包中若带图纸,网页内容里面会有图纸预览,若没有图纸预览就没有图纸。
  • 4. 未经权益所有人同意不得将文件中的内容挪作商业或盈利用途。
  • 5. 人人文库网仅提供信息存储空间,仅对用户上传内容的表现方式做保护处理,对用户上传分享的文档内容本身不做任何修改或编辑,并不能对任何下载内容负责。
  • 6. 下载文件中如有侵权或不适当内容,请与我们联系,我们立即纠正。
  • 7. 本站不保证下载资源的准确性、安全性和完整性, 同时也不承担用户因使用这些下载资源对自己和他人造成任何形式的伤害或损失。

评论

0/150

提交评论